- Also known as
- ACTH(4-7)PGP · ACTH(4-10) analogue · Semax peptide · Met-Glu-His-Phe-Pro-Gly-Pro
- Class
- Synthetic ACTH(4-10) analogue (heptapeptide)
- Form
- Lyophilised powder in 10 mg vials, plus a ready-mixed nasal spray
- Sizes
- 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL
What is Semax?
Semax is classed as a synthetic ACTH(4-10) analogue (heptapeptide), and that classification is the starting point for the published work. The literature on it spans rat, human and mouse models. The same material appears under several names in the literature, among them ACTH(4-7)PGP, ACTH(4-10) analogue and Semax peptide. Its recorded sequence is Met-Glu-His-Phe-Pro-Gly-Pro: ACTH(4-7) with a C-terminal Pro-Gly-Pro. Of the 8 references below, one is a controlled human trial. It comes as lyophilised powder in 10 mg vials and a ready-mixed nasal spray, kept in Canadian stock for laboratory research. This is not a drug and is not offered for any use in a person or an animal.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Gusev EI et al.2018 · Zh Nevrol Psikhiatr Im S S Korsakova · PMID 29798983 | Human, controlled clinical study, ischaemic stroke rehabilitation (n=110) | 6000 mcg/day | Two 10-day courses with a 20-day interval; patients followed for about 5 months | Semax raised plasma BDNF, which stayed high through the study, regardless of when rehabilitation started. Semax and high BDNF were associated with faster improvement and a better final Barthel index score. |
| Gusev EI et al.1997 · Zh Nevrol Psikhiatr Im S S Korsakova · PMID 11517472 | Human, controlled clinical trial, acute hemispheric ischaemic stroke (n=30 Semax, 80 conventional-therapy controls) | 12 mg/day (moderate stroke) and 18 mg/day (severe stroke) were reported as the most effective daily doses | 5- and 10-day courses | Adding Semax to standard intensive therapy had some influence on the rate of recovery of neurological function, particularly motor deficits, assessed with clinical scales, EEG mapping and somatosensory evoked potentials. |
| Lebedeva IS et al.2018 · Bull Exp Biol Med · PMID 30225715 | Human, placebo-controlled resting-state fMRI study in healthy volunteers (n=24: 14 Semax, 10 placebo) | Intranasal 1% Semax (volume not stated in the abstract) | Single administration; scans before and 5 and 20 min after | The Semax group showed a greater volume of the rostral (medial frontal cortex) subcomponent of the default mode network than the placebo group. |
| Ivanikov IO et al.2002 · Bull Exp Biol Med · PMID 12459874 | Human, controlled clinical study, refractory peptic ulcer (n not stated in the abstract) | Intranasal 1% solution, 2–4 drops three times a day, alongside omeprazole, De-Nol and Solcoseryl | 10 days; healing assessed on day 14 | Ulcer healing on day 14 was seen in 89.5% of patients given intranasal Semax versus 30.8% of controls. The authors call for further clinical studies. |
| Gusev EI et al.2005 · Zh Nevrol Psikhiatr Im S S Korsakova · PMID 15792140 | Human, comparative study, cerebrovascular insufficiency (n=187) | Not stated in the abstract | Not stated in the abstract | Semax was associated with clinical improvement, stabilisation of disease progress and a reduced risk of stroke and transient ischaemic attack. The authors report a minor percentage of side effects and good tolerability, including in older patients. |
| Filippenkov IB et al.2020 · Genes (Basel) · PMID 32580520 | Rat, transient middle cerebral artery occlusion (tMCAO) model | Not stated in the abstract | Brain tissue analysed 24 h after tMCAO | RNA-Seq found 394 differentially expressed genes with Semax versus saline. Semax suppressed inflammation-related genes and activated neurotransmission-related genes, the reverse of the pattern seen with ischaemia-reperfusion alone. |
| Shadrina M et al.2010 · J Mol Neurosci · PMID 19662538 | Rat (male Wistar), gene expression in hippocampus, frontal cortex and retina | Not stated in the abstract | Tissue sampled from 20 min to 24 h after administration | NGF and BDNF expression moved in different directions by tissue: both fell in the hippocampus and retina at 20 min and rose in the frontal cortex, and retinal BDNF rose significantly by 90 min. |
| Liu R et al.2025 · Br J Pharmacol · PMID 40692165 | Mouse (female C57BL/6), spinal cord injury at T9-T10; PC12 cell neuroinflammation model | Not stated in the abstract | Not stated in the abstract | Semax improved functional recovery scores and reduced lysosomal membrane permeabilisation-related pyroptosis and oxidative stress. The authors link the effect to the μ-opioid receptor and the deubiquitinase USP18. |
What these studies don't show: Controlled trials do exist, but the questions they answer are narrow. Trial groups are picked, the endpoints are often surrogate markers rather than real outcomes, and follow-up seldom lasts long. The results apply to the setting studied and no further. Testing confirms identity and purity; it is not evidence of an effect.
Every study links to its PubMed record. See all Semax studies in the research library →
Semax price in Canada: 10mg vial
Buy Semax in Canada in a 10mg vial, plus a nasal spray and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $52.00 | $5.20/mg |
Other formats and kits
Is Semax available in Canada?
No Semax-containing product carries a Drug Identification Number in Canada. This means Health Canada has not assessed it for safety, efficacy or quality. Borealis Peptides stocks it for in-vitro research only; it goes out for use in no living subject. How Health Canada treats research peptides →
Side effects reported in studies
Every statement here is linked to the study that recorded it. Tolerability observations from the cited papers appear below in the authors' own words. Human work on this scale does not establish a safety profile. Read more →
Doses used in studies
Semax FAQ
What is Semax?
Semax is a synthetic ACTH(4-10) analogue (heptapeptide), and that classification is the starting point for the published work. Its published record is drawn from rat, human and mouse work. Borealis Peptides provides it as lyophilised powder in 10 mg vials and a ready-mixed nasal spray for in-vitro laboratory research. It holds no medicine authorization and is not for use in any living subject. The studies behind it are listed on this page with the model each one used and what the authors reported.
Where can I buy Semax in Canada?
It is dispatched within Canada from the stock we keep, in 10 mg vials. Nothing goes out without HPLC confirmation of identity and purity for that batch. Borealis Peptides takes research orders only and ships to research and business addresses. Identity and purity are checked per batch, and the paperwork names that specific batch.
Is Semax legal in Canada?
No Semax-containing product carries a Drug Identification Number in Canada. This means Health Canada has not assessed it for safety, efficacy or quality. Borealis Peptides carries it for in-vitro research and offers it for use in no living subject. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so it tells us what the material is supplied for and nothing about permission to use it. Establishing lawful use in your own setting is up to you.
How much Semax should I use?
We do not field dosing questions. Semax is not provided for use in a person or an animal, so there is no dose to set out. What the page carries is the quantity each cited study used and the model it was used in, reproduced as the authors published it.
What human evidence is there for Semax?
One of the 8 cited studies is a controlled trial in people, and the remainder are animal or cell work. Each row lists its model, the amount used and the authors' reported outcome, so every study can be weighed on its own terms instead of through a summary.
How is Semax stored?
Keep sealed vials at −20 °C, dry and dark. Once mixed, storage is 2–8 °C. The lyophilised powder withstands ambient temperature in transit, so it travels without ice and goes into the fridge on arrival. The genuine risks are repeated freeze-thaw cycles and light exposure, not the shipping itself.
Does Semax need bacteriostatic water?
The nasal spray comes as a finished solution in its own bottle, so nothing needs adding: no bacteriostatic water, no mixing, no transfer. Only the lyophilised vial ships dry, and that is the single format to which bacteriostatic water applies. It is sold separately.
How is the purity of Semax confirmed?
HPLC testing is done on every batch before sale, and the certificate points to the batch in your vial rather than to the product as a whole. Holding on to that batch number alongside your records is what lets an observation be reproduced later. Certificates can be supplied on request.
How does Semax compare with Selank and DSIP?
They are distinct compounds with distinct literatures, and no ranking is given here. Selank and DSIP have 8 cited studies and 8 cited studies on their page against 8 here. The comparison that helps is between the two study tables and the models behind them.
Why is Semax named in a Health Canada advisory?
Because it was one of the peptides seized from sellers offering unauthorized injectable products online. That advisory deals with material sold for people to inject without authorization. What Borealis Peptides sells is research material for the laboratory bench, never anything for injection or for any use in a person, and that distinction is the one the advisory turns on.








